Clinical and dermoscopic assessment of ablative carbon dioxide laser versus intradermal heparin sodium in xanthelasma

Abstract

AbstractBackgroundAblative carbon dioxide (CO2) laser is still a cornerstone in the management of xanthelasma. However, post‐laser complications such as post‐inflammatory hyperpigmentation or scarring have to be considered. Heparin sodium was recently suggested as an effective therapeutic modality for xanthelasma.ObjectiveThe aim of this work was to compare the therapeutic value of ablative CO2 laser versus intradermal heparin sodium in xanthelasma.MethodsThis study was piloted on 30 xanthelasma patients, whose lesions were randomly categorized into two groups. Group A was managed with CO2 laser ablation (2 sessions scheduled every 4 weeks), whereas Group B was managed with intradermal heparin sodium injections (10 sessions scheduled every week). Pre‐ and post‐treatments evaluations were done both clinically and dermoscopically.ResultsSignificant reduction of xanthelasma lesions was reported in response to both therapeutic interventions. However, the ablative CO2 laser was more significantly effective than intradermal heparin sodium. Interestingly, intradermal injection of heparin sodium was nearly as effective as ablative CO2 laser in early (<2 years duration) grade I and II xanthelasma, with a lower incidence of post‐therapy side effects.ConclusionsIntradermal injection of heparin sodium could be suggested as a safe and cost‐effective therapeutic technique for early mild grade I and II xanthelasma. Moreover, it could be recommended as a pre‐operative management of grade III and IV xanthelasma to reduce the lesions to be easily ablated with CO2 laser.